Does FIT have a role in the detection of small bowel pathology: a prospective study.

IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Therapeutic Advances in Gastrointestinal Endoscopy Pub Date : 2024-11-26 eCollection Date: 2024-01-01 DOI:10.1177/26317745241301553
Priya Oka, Calvin M Johnson, Mark McAlindon, Reena Sidhu
{"title":"Does FIT have a role in the detection of small bowel pathology: a prospective study.","authors":"Priya Oka, Calvin M Johnson, Mark McAlindon, Reena Sidhu","doi":"10.1177/26317745241301553","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The faecal immunochemical test (FIT) is an immunoassay used to detect human blood in the stool. The role of FIT as a screening tool for small bowel pathology remains unclear.</p><p><strong>Objectives: </strong>This study aimed to investigate the role of FIT in predicting small bowel pathology in patients with iron deficiency anaemia (IDA).</p><p><strong>Design: </strong>This was a single tertiary centre prospective study. The inclusion criterion was adults (⩾18 years and <80 years) with IDA who were referred to secondary care for endoscopic investigations.</p><p><strong>Methods: </strong>All patients had a FIT test done in primary care. Eligible patients were invited to have a small bowel capsule endoscopy (SBCE) prior to endoscopy. Patients with subsequent upper or lower gastrointestinal tract malignancy were excluded from the study. IDA was defined as a Hb < 131 g/L for men and <110 g/L for women with ferritin <30 µg/L and/or iron levels <11 µmol/L. A further 100 patients with recurrent/refractory IDA who did not have a FIT test done and had an SBCE were used as the control group.</p><p><strong>Results: </strong>In total 179 patients were included in the final analysis with a median age of 64.5 years (interquartile range (IQR 51-75)); haemoglobin 101 (IQR 90-111) and ferritin 11(7-20). In the prospective FIT group of 79 patients, there were 35 (44%) patients with significant findings on SBCE which was classed as contributing to IDA. These findings included angioectasia in <i>n</i> = 21 (26.6%) patients which was the most common finding. The other findings included erosions and ulcers = 5 (7.6%); inflammatory strictures = 3 (3.8%); active Crohn's <i>n</i> = 1 (1.3%); visible blood with no clear source <i>n</i> = 3 (3.8%) and bleeding angioectasia <i>n</i> = 1 (1.3%). A positive FIT (>10) had a sensitivity, specificity, positive predictive value and negative predictive value of 34.29%, 54.55%, 37.5% and 51.08%, respectively. In the control group (<i>n</i> = 100), 37% of the patients had significant pathology on SBCE. On logistic regression, age (OR 1.06; 95% CI: 1.03-1.11) was the only factor related to the probability of having a positive finding on SBCE.</p><p><strong>Conclusion: </strong>Over a third of the patients with IDA have significant findings on SBCE. However, in this study, we did not find that FIT conferred any additional benefit in the detection of small bowel pathology.</p>","PeriodicalId":40947,"journal":{"name":"Therapeutic Advances in Gastrointestinal Endoscopy","volume":"17 ","pages":"26317745241301553"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastrointestinal Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26317745241301553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The faecal immunochemical test (FIT) is an immunoassay used to detect human blood in the stool. The role of FIT as a screening tool for small bowel pathology remains unclear.

Objectives: This study aimed to investigate the role of FIT in predicting small bowel pathology in patients with iron deficiency anaemia (IDA).

Design: This was a single tertiary centre prospective study. The inclusion criterion was adults (⩾18 years and <80 years) with IDA who were referred to secondary care for endoscopic investigations.

Methods: All patients had a FIT test done in primary care. Eligible patients were invited to have a small bowel capsule endoscopy (SBCE) prior to endoscopy. Patients with subsequent upper or lower gastrointestinal tract malignancy were excluded from the study. IDA was defined as a Hb < 131 g/L for men and <110 g/L for women with ferritin <30 µg/L and/or iron levels <11 µmol/L. A further 100 patients with recurrent/refractory IDA who did not have a FIT test done and had an SBCE were used as the control group.

Results: In total 179 patients were included in the final analysis with a median age of 64.5 years (interquartile range (IQR 51-75)); haemoglobin 101 (IQR 90-111) and ferritin 11(7-20). In the prospective FIT group of 79 patients, there were 35 (44%) patients with significant findings on SBCE which was classed as contributing to IDA. These findings included angioectasia in n = 21 (26.6%) patients which was the most common finding. The other findings included erosions and ulcers = 5 (7.6%); inflammatory strictures = 3 (3.8%); active Crohn's n = 1 (1.3%); visible blood with no clear source n = 3 (3.8%) and bleeding angioectasia n = 1 (1.3%). A positive FIT (>10) had a sensitivity, specificity, positive predictive value and negative predictive value of 34.29%, 54.55%, 37.5% and 51.08%, respectively. In the control group (n = 100), 37% of the patients had significant pathology on SBCE. On logistic regression, age (OR 1.06; 95% CI: 1.03-1.11) was the only factor related to the probability of having a positive finding on SBCE.

Conclusion: Over a third of the patients with IDA have significant findings on SBCE. However, in this study, we did not find that FIT conferred any additional benefit in the detection of small bowel pathology.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FIT在小肠病理检测中的作用:一项前瞻性研究。
背景:粪便免疫化学试验(FIT)是一种用于检测人粪便中的血液的免疫测定方法。FIT作为小肠病理筛查工具的作用尚不清楚。目的:本研究旨在探讨FIT在预测缺铁性贫血(IDA)患者小肠病理中的作用。设计:这是一项单三级中心前瞻性研究。纳入标准是成年人(大于或等于18岁)和方法:所有患者在初级保健中都进行了FIT测试。符合条件的患者在内镜检查前接受小肠胶囊内镜检查(SBCE)。随后出现上消化道或下消化道恶性肿瘤的患者被排除在研究之外。结果:最终分析共纳入179例患者,中位年龄为64.5岁(四分位数范围(IQR 51-75));血红蛋白101 (IQR 90-111)和铁蛋白11(7-20)。在79例患者的前瞻性FIT组中,有35例(44%)患者在SBCE方面有显著发现,被归类为导致IDA。这些发现包括最常见的血管扩张n = 21(26.6%)例患者。其他发现包括糜烂和溃疡= 5例(7.6%);炎性狭窄= 3例(3.8%);活动性克罗恩病n = 1 (1.3%);来源不明可见血3例(3.8%),血管扩张出血1例(1.3%)。FIT阳性(bbb10)的敏感性、特异性、阳性预测值和阴性预测值分别为34.29%、54.55%、37.5%和51.08%。在对照组(n = 100)中,37%的患者在SBCE上有明显的病理。logistic回归分析,年龄(OR 1.06;95% CI: 1.03-1.11)是与SBCE阳性发现概率相关的唯一因素。结论:超过三分之一的IDA患者在SBCE上有显著的发现。然而,在这项研究中,我们没有发现FIT在小肠病理检测中有任何额外的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.80
自引率
0.00%
发文量
8
审稿时长
13 weeks
期刊最新文献
Clinical outcomes and risk factors of post-polypectomy microperforation in patients with colorectal neoplasia: a case-control study. Application of artificial intelligence in gastrointestinal endoscopy in Vietnam: a narrative review. Does FIT have a role in the detection of small bowel pathology: a prospective study. Endoscopic ultrasound-guided placement of lumen-apposing metal stent for transgastric drainage of loculated malignant ascites. Effectiveness of endoscopic ultrasound-guided simple puncture-aspiration (non-stenting) in the management of abdominal collections.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1